Skip to main content

BridgeBio Oncology Therapeutics, Inc.

corporate_fare Company Profile

BridgeBio Oncology Therapeutics, Inc.

BBOT·NASDAQ·Life Sciences·CIK 0001869105

BBOT is a clinical-stage biotechnology company focused on developing therapies for patients with cancers driven by RAS and PI3Kα. These are frequently mutated oncogenes that contribute to uncontrolled tumor growth in cancers such as lung, breast, pancreas, and colon cancer. RAS mutations are found in approximately 30% of all human cancers. The company's pipeline includes three orally bioavailable small molecule inhibitors. These inhibitors are designed to achieve high levels of target inhibition against oncogenic drivers while maintaining a favorable tolerability profile. BBOT aims to provide significant benefit to patients beyond standard care, including potential benefits for KRAS mutant tumors through combination therapies. BBOT's programs, BBO-8520 (direct KRAS G12C ON/OFF) and BBO-11818 (direct panKRAS ON/OFF), target KRAS, which is the most mutated oncogene. KRAS is a protein that switches between an active "ON" state and an inactive "OFF" state. Oncogenic mutations in KRAS disrupt this balance, increasing the "ON" state and leading to uncontrolled cell growth and cancer progression. Most KRAS mutations occur in codon 12. In non-small cell lung cancer (NSCLC), KRAS G12C mutations are present in approximately 15% of patients. While the FDA approved the first KRAS G12C-targeting therapeutic in 2021, these first-generation drugs exclusively target the "OFF" state, which can lead to adaptive resistance and limit efficacy and durability. Patients treated with "OFF" state inhibitors also experience significant toxicities, which are worse when combined with immune checkpoint inhibitors (ICI).

BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for BBOT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for BBOT spans 10-Q, 8-K, 424B3, 10-K.

Recent high-impact activity:

  • BBOT Q3 10-Q: Loss Narrows to $34.2M, Cash $315.3M, Prior EPS Restated
  • BBOT Q3 Loss Narrows to $34.2M; Cash Runway Extended Into 2029
  • BBOT Reports 75% ORR for BBO-8520 + Pembrolizumab in G12C Inhibitor-Experienced NSCLC
  • BBOT Q2 2026: Net Loss Widens to $56.5M as Pipeline Spending Ramps; Cash Runway into 2028
  • BBOT Posts $56.5M Q2 Loss, Extends Cash Runway into 2028, and Advances KRAS Pipeline

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$134.04M
Diluted EPS
-$4.30
Op. Cash Flow
-$113.89M
Free Cash Flow
-$114.5M
Operating Income
-$145.82M
Cash & Equivalents
$373.69M
Debt / Equity
0.00×
Shares Outstanding
79.99M sh
Source: 10-K · filed 2026-03-05 · accession 0001193125-26-094112

Short Interest & Short Volume

5.10 days to cover

FINRA reported short interest of 3,468,496 shares in BBOT as of the October 30, 2026 settlement, a 9.8% decrease from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 51.7% of BBOT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,468,496 shares as of October 30, 2026
Change vs prior period▼ 9.8%
Days to cover5.10 at avg daily volume of 680,248
Daily short volume (FINRA facilities)51.7% of 166,540 shares on November 20, 2026
5-day average short volume55.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for BBOT, detected from its recent SEC filings.

ATM program1 shelf registration

$500M Universal Shelf Registered · $200M ATM Program Established

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with B →
$1.81
52-week range · as of 2026-11-10 $1.81 – $14.87
Market cap
$145.25M
Volume
451.1K (0.7× avg)
3-mo avg 632.8K
Live data · 2026-11-21 12:41 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BBOT - Latest Insights

BBOT
Nov 10, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $1.81 info
Change: -$0.370 (-17%) info
Market Cap: $145.255M info
BBOT
Nov 10, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $1.81 info
Change: -$0.370 (-17%) info
Market Cap: $145.255M info
BBOT
Sep 08, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.77
Real-time Price: $1.81 info
Change: -$6.96 (-79%) info
Market Cap: $145.255M info
BBOT
Aug 11, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $1.81 info
Change: -$7.39 (-80%) info
Market Cap: $145.255M info
BBOT
Aug 11, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $1.81 info
Change: -$7.39 (-80%) info
Market Cap: $145.255M info
BBOT
May 12, 2026, 5:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $8.13
Real-time Price: $1.81 info
Change: -$6.32 (-78%) info
Market Cap: $145.255M info
BBOT
May 12, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.13
Real-time Price: $1.81 info
Change: -$6.32 (-78%) info
Market Cap: $145.255M info
BBOT
May 12, 2026, 5:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $8.13
Real-time Price: $1.81 info
Change: -$6.32 (-78%) info
Market Cap: $145.255M info
BBOT
May 06, 2026, 4:06 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $8.49
Real-time Price: $1.81 info
Change: -$6.68 (-79%) info
Market Cap: $145.255M info
BBOT
Apr 22, 2026, 5:56 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $9.50
Real-time Price: $1.81 info
Change: -$7.69 (-81%) info
Market Cap: $145.255M info
BBOT
Apr 22, 2026, 5:31 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.50
Real-time Price: $1.81 info
Change: -$7.69 (-81%) info
Market Cap: $145.255M info
BBOT
Apr 22, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $8.87
Real-time Price: $1.81 info
Change: -$7.06 (-80%) info
Market Cap: $145.255M info
BBOT
Apr 20, 2026, 5:58 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $9.80
Real-time Price: $1.81 info
Change: -$7.99 (-82%) info
Market Cap: $145.255M info
BBOT
Mar 06, 2026, 10:07 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.36
Real-time Price: $1.81 info
Change: -$8.55 (-83%) info
Market Cap: $145.255M info
BBOT
Mar 05, 2026, 4:40 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $9.89
Real-time Price: $1.81 info
Change: -$8.08 (-82%) info
Market Cap: $145.255M info
BBOT
Mar 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.89
Real-time Price: $1.81 info
Change: -$8.08 (-82%) info
Market Cap: $145.255M info
BBOT
Jan 07, 2026, 7:15 AM EST
Filing Type: 424B3
Importance Score:
9
Price at Filing: $12.08
Real-time Price: $1.81 info
Change: -$10.27 (-85%) info
Market Cap: $145.255M info
BBOT
Jan 07, 2026, 7:12 AM EST
Filing Type: 424B3
Importance Score:
8
Price at Filing: $11.59
Real-time Price: $1.81 info
Change: -$9.78 (-84%) info
Market Cap: $145.255M info
BBOT
Jan 07, 2026, 7:09 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.59
Real-time Price: $1.81 info
Change: -$9.78 (-84%) info
Market Cap: $145.255M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets